Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
Anthony Traboulsee(University of British Columbia), Brian G. Weinshenker(Mayo Clinic in Arizona), Jeffrey L. Bennett(University of Colorado Denver), Svitlana Shkrobot(I.Horbachevsky Ternopil National Medical University), Edward Fox(Penn State Milton S. Hershey Medical Center), Takashi Yamamura(National Center of Neurology and Psychiatry), Hideki Garren(Io Therapeutics (United States)), Athos Gianella-Borradori(Servier (France)), L Szczechowski(Medical University of Silesia), Yusuke Terada, Benjamin Greenberg(Centre Hospitalier Universitaire de Martinique), Pádraig Wright, Yuichi Kawata
Cited by 495
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k